Investor Relations

Press Releases

Phase 2 Study of Advaxis's Axalimogene Filolisbac (ADXS-HPV) in Cervical Cancer to be Presented at 2015 AGOS Annual Meeting

Read More

Advaxis Announces Licensing Agreement With Knight Therapeutics and Raises $25 Million Through Direct Investments From Knight and Sectoral Asset Management

Read More

Advaxis and MedImmune Commence Enrollment in Phase I/II Study of Axalimogene Filolisbac (ADXS-HPV) in Combination With Durvalumab (MEDI4736) for the Treatment of HPV-Associated Cancers

Read More

Advaxis Appoints Tom Ridge, America's First Secretary of Homeland Security and 43rd Governor of Pennsylvania, to Board of Directors

Read More

Advaxis's ADXS-PSA Awarded Research Grants From the Prostate Cancer Foundation and the Movember Foundation

Read More

Advaxis's Scientific Founder to Present on ADXS-HER2 at World Congress on Breast Cancer 2015

Read More

Advaxis Expands Intellectual Property for Lm Technology(TM) Platform in HER2

Read More

Advaxis Appoints Dr. Shelonitda S. Rose as Vice President, Clinical Development

Read More

Advaxis's President and Chief Executive Officer Daniel J. O'Connor Receives 2015 Ernst & Young Entrepreneur Of The Year® in New Jersey

Read More

Advaxis Provides 2015 Half-Year Review and Outlook

Read More